The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 39-44 , July 2010

Practical approach to the patient with hypereosinophilia

  • Florence Roufosse, MD

      Affiliations

    • Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, and the Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
    • ,
  • Peter F. Weller, MD

      Affiliations

    • Department of Medicine, Division of Infectious Diseases and Division of Allergy and Inflammation, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Mass
    • Corresponding Author InformationReprint requests: Peter F. Weller, MD, Beth Israel Deaconess Medical Center, CLS 943, 330 Brookline Ave, Boston, MA 02215.

Received 2 February 2010 ,Revised 18 April 2010 ,Accepted 19 April 2010.

References 

  1. Simon H-U, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126:45–49
  2. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007;27:357–375
  3. Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol. 2009;101:81–121
  4. Spencer LA, Szela CT, Perez SA, Kirchhoffer CL, Neves JS, Radke AL, et al. Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol. 2009;85:117–123
  5. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033–1039
  6. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1–27
  7. Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med. 2009;60:293–306
  8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  9. Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27:377–388
  10. Tefferi A, Gotlib J, Pardanni A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010;85:158–164
  11. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:389–413
  12. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–1325
  13. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951

 Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(10)00660-3

doi: 10.1016/j.jaci.2010.04.011

The Journal of Allergy and Clinical Immunology
Volume 126, Issue 1 , Pages 39-44 , July 2010

Article Tools

* Image Usage & Resolution